FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal By Ogkologos - June 20, 2025 778 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Presence of Tumour and Higher Levels of LAG3-positive T-cells in the... November 11, 2025 FDA Grants Accelerated Approval to Lisocabtagene Maraleucel for Follicular Lymphoma June 3, 2024 Study Estimates That 22% Of Breast Cancers Are Overdiagnosed And Won’t... January 30, 2020 Cancer Immunotherapy Drug Simultaneously Targets Two Proteins that Block Immune Response April 4, 2018 Load more HOT NEWS 7 Tips For Keeping The Entire Family Healthy During Flu Season ¿Puede una biopsia hacer que mi cáncer se disemine? Active Monitoring Promising for Women with Low-Risk Ductal Carcinoma In Situ Repurposing radiotherapy drugs could give immunotherapy a boost
